SCHEMBL3755620

SCHEMBL3755620

N#Cc1cccc(-c2ncc3cn[nH]c3n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 9/20 0.54
IDO1 P14902 2/20 0.51
CYP1A2 P05177 8/20 0.46
CYP3A4 P08684 7/20 0.46
CYP2C19 P33261 6/20 0.46
CYP2D6 P10635 4/20 0.46
LMNA P02545 4/20 0.46
ALDH1A1 P00352 6/20 0.46
MAPK1 P28482 5/20 0.46
HSD17B10 Q99714 4/20 0.46
ALOX15 P16050 3/20 0.46
TSHR P16473 3/20 0.46
DYRK1A Q13627 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
RAF1 P04049 2/20 0.43
BRAF P15056 2/20 0.43
TP53 P04637 3/20 0.43
USP2 O75604 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755550 0.78 IDO1 (0.47) IDO1CYP1A2ALDH1A1CYP2C9KDM4E
SCHEMBL3757242 0.78 METAP2 (0.47) CLK4CYP1A2DYRK1A
SCHEMBL2038868 0.77 CLK4 (0.62) CLK4IDO1CYP1A2CYP3A4CYP2C19
SCHEMBL31392594 0.77 CLK4 (0.57) CLK4IDO1CYP1A2CYP3A4CYP2C19
SCHEMBL3762000 0.76 HPGDS (0.47) CLK4IDO1CYP1A2LMNADYRK1A
SCHEMBL2476819 0.74 CLK4 (0.71) CLK4IDO1CYP1A2CYP3A4CYP2C19
SCHEMBL18114562 0.73 ROCK2 (0.61)
SCHEMBL11938358 0.72 CLK4 (0.69) CLK4IDO1CYP1A2CYP3A4CYP2C19
SCHEMBL18482894 0.72 CLK4 (0.69) CLK4IDO1CYP1A2CYP3A4CYP2C19
SCHEMBL28850273 0.71 CLK4 (0.51) CLK4CYP1A2CYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 US claimed
US-8349847-B2 Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents KONAKANCHI DURGA PRASAD (IN) 2013-01-08 US disclosed
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS DPYD, TYMP, TYMS CLK4 2786/4885IDO1 1872/4885CYP1A2 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.